Amadeus Capital and Jonathan Milner have teamed up to invest in Healx, a startup working with patient advocacy groups to repurpose drugs for rare diseases.
Recursion Pharmaceuticals has raised $12.9 million to scale up its computer-driven approach to drug development.
UC San Francisco has landed $24 million in National Science Foundation funding to set up the Center for Cellular Construction.
British startup BenevolentAI has become the first European firm to install a purpose-built version of the DGX-1, a supercomputer designed for deep learning.
Antidote, the tech startup formerly known as TrialReach, is gearing up to introduce a tool to automatically match patients’ EHRs to clinical trials.
AOBiome is running an iPhone-enabled Phase IIb trial of its bacterial treatment for acne with Novartis ($NVS)-backed virtual trial CRO Science 37.
Researchers have found 110 antiviral targets and several existing drugs that may hit them using gene-trap insertional mutagenesis and a computational framework…
In a recent effort to characterize new targets of obesity, a collaborative effort has suggested a new mechanism that regulates obesity in the mouse’s brain.
A consortium of cancer centers has contracted HudsonAlpha Institute of Biotechnology to sequence 20,000 samples by 2019.
Medidata has signed up to provide its cloud platform and mobile health capabilities to Techfields Pharma.